Diltiazem Hydrochloride, nondihydropyridine-derivative, is a member of the group of drugs known as benzothiazepines, which are a class of calcium channel blockers, used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. It is a class III anti-anginal drug, and a class IV antiarrhythmic [1]. Diltiazem Hydrochloride exerts its pharmacological action through inhibiting trans-membrane influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells, without changing serum calcium concentrations. It is a peripheral arterial vasodilator that acts directly on vascular smooth muscle causing reduction in peripheral vascular resistance and blood pressure. It possesses substantial inhibitory effects on the cardiac conduction system, acting principally at the atrioventricular (AV) node to slow conduction time and prolong AV nodal refractoriness. In spite of being a corner stone in the treatment and management of hypertension, angina and arrhythmia, it experiences a major pharmacokinetic problem. Despite the fact that fol...